MAP3K5 and ovarian carcinoma: Interestingly, treatment with IN8, SP600125 or ibrutinib essentially enhanced the sensitivity to platinum-based (cisplatin, DDP) chemotherapy, suggesting that the combination of ASK1/JNK pathway inhibition and platinum-based chemotherapy might represent a therapeutic strategy in ovarian cancer.